-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Enterprise News] On July 15, Sihuan Pharmaceutical issued an announcement saying that the company intends to propose to sell some or all of the imitation products that do not meet the company's performance expectations or do not meet the company's long-term strategic goals due to the impact of changes in the pharmaceutical industry and polici.
Pharmaceutical and other non-core traditional medicine businesses and asse.
According to the arrangement, the company intends to gradually complete the aforesaid potential disposal in the next 12-24 mont.
Its specific scope is finalized depending on market conditions and negotiations with potential buye.
According to the data, Sihuan Pharmaceutical is a Hong Kong investment holding company engaged in the pharmaceutical busine.
The company is mainly engaged in the research and development, manufacturing and sales of drugs, covering cardiovascular and cerebrovascular, central nervous system, metabolism, tumor and anti-infection fiel.
The generic drug business is the main source of revenue for Sihuan Pharmaceutic.
However, the company also has a layout of medical cosmetology and innovative medicine trac.
It deploys medical cosmetology through self-research, mergers and acquisitions, cooperation, and authorizati.
In the context of the recent boom in medical cosmetology, it is regarded by the industry as a dark horse in the medical cosmetology tra.
At the same time, Xuanzhu Bio, a subsidiary company it acquired, is one of the few platform-based innovative drug companies in China that has independent research and development capabilities in both small and macromolecular fiel.
It has a rich research and development pipeline and is about to usher in the product harvest peri.
In addition, its non-wholly-owned subsidiary, Huisheng Bio, is one of the few companies in China that has a full product coverage in the field of diabetes and complications, and has dozens of potential diabetes and complications R&D product pipelin.
The 2021 annual report shows that the company's revenue is 291 billion yuan, a year-on-year increase of 3Among them, the revenue of medical beauty products was about 400 million yuan, an increase of 1383% year-on-year; the revenue of innovative drugs and other drugs was 294 million yuan, an increase of 20% year-on-year; the revenue of generic drugs was 598 billion yuan, an increase of 12% year-on-ye.
It can be seen from the annual report that although the generic drug business is the company's main source of revenue, its growth rate is obviously slower than that of medical beauty and innovative dru.
Behind the sluggish growth of its generic drug business, it is mainly related to a series of pharmaceutical industry policies that focus on monitoring rational drug use, medical insurance negotiation, and centralized procurement in recent yea.
It is reported that in 2019, seven core products including Cerebroside Carnosine Injection under Sihuan Pharmaceutical were included in the first batch of national key monitoring and rational drug use catalogu.
In 2018, sales reached 382 billion yuan, accounting for more than 80% of the year's reven.
What has also changed is the company's performan.
The company's gross profit margin began to decline year by year after reaching a peak of 85% in 20175%, 77% and 74% in 2019, 2020 and 2021, respective.
In this regard, the company also mentioned in the relevant annual report that it was caused by the sharp decline in the sales of drugs in the original key monitoring catalog with high gross profit and the centralized procureme.
In the 2021 annual report, Sihuan Pharmaceutical believes that the current generic drug business has increased by 12% year-on-year, showing that the impact of the key monitoring catalog products on the company's generic drug business has come to an end, and the performance of the generic drug segment has officially entered the rising channel, but the clinical value is not hi.
A shrinking market for well-defined drugs and high-priced generics is a foregone conclusi.
From this point of view, Sihuan Pharmaceutical's decision to divest the generic drug business at this time is also justifiab.
After the sale of the generic drug business, the company's focus will also shift to the medical beauty and innovative drug busine.
For innovative drugs, the company had planned to spin off Xuanzhu Biotechnology .
, L.
and list it independently on the Shanghai Stock Exchange's Science and Technology Innovation Boa.
The industry believes this may help companies increase their financial flexibility and ability to raise external capit.
At the same time, Sihuan Pharmaceutical directly holds about 639% of the entire issued share capital of Xuanzhu B.
After the completion of the spin-off and listing, it will still be the controlling shareholder of Xuanzhu Bio, and will still benefit from .
In terms of medical beauty, Beijing Meiyan Space, a medical beauty platform under Sihuan Pharmaceutical, is the exclusive agent of South Korea’s Hugel’s blockbuster product “Le Tibao”, which was approved in China at the end of 2020, becoming the fourth type A meat to be approved for listing in China Poisonous toxi.
In addition, the company currently has more than 10 products under research in China, including Tongyan needles, girls needles, collagen and lipolysis produc.
All the above agents and self-developed medical and beauty products are expected to be launched in the next three to four yea.
Approved for listi.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Pharmaceutical and other non-core traditional medicine businesses and asse.
According to the arrangement, the company intends to gradually complete the aforesaid potential disposal in the next 12-24 mont.
Its specific scope is finalized depending on market conditions and negotiations with potential buye.
According to the data, Sihuan Pharmaceutical is a Hong Kong investment holding company engaged in the pharmaceutical busine.
The company is mainly engaged in the research and development, manufacturing and sales of drugs, covering cardiovascular and cerebrovascular, central nervous system, metabolism, tumor and anti-infection fiel.
The generic drug business is the main source of revenue for Sihuan Pharmaceutic.
However, the company also has a layout of medical cosmetology and innovative medicine trac.
It deploys medical cosmetology through self-research, mergers and acquisitions, cooperation, and authorizati.
In the context of the recent boom in medical cosmetology, it is regarded by the industry as a dark horse in the medical cosmetology tra.
At the same time, Xuanzhu Bio, a subsidiary company it acquired, is one of the few platform-based innovative drug companies in China that has independent research and development capabilities in both small and macromolecular fiel.
It has a rich research and development pipeline and is about to usher in the product harvest peri.
In addition, its non-wholly-owned subsidiary, Huisheng Bio, is one of the few companies in China that has a full product coverage in the field of diabetes and complications, and has dozens of potential diabetes and complications R&D product pipelin.
The 2021 annual report shows that the company's revenue is 291 billion yuan, a year-on-year increase of 3Among them, the revenue of medical beauty products was about 400 million yuan, an increase of 1383% year-on-year; the revenue of innovative drugs and other drugs was 294 million yuan, an increase of 20% year-on-year; the revenue of generic drugs was 598 billion yuan, an increase of 12% year-on-ye.
It can be seen from the annual report that although the generic drug business is the company's main source of revenue, its growth rate is obviously slower than that of medical beauty and innovative dru.
Behind the sluggish growth of its generic drug business, it is mainly related to a series of pharmaceutical industry policies that focus on monitoring rational drug use, medical insurance negotiation, and centralized procurement in recent yea.
It is reported that in 2019, seven core products including Cerebroside Carnosine Injection under Sihuan Pharmaceutical were included in the first batch of national key monitoring and rational drug use catalogu.
In 2018, sales reached 382 billion yuan, accounting for more than 80% of the year's reven.
What has also changed is the company's performan.
The company's gross profit margin began to decline year by year after reaching a peak of 85% in 20175%, 77% and 74% in 2019, 2020 and 2021, respective.
In this regard, the company also mentioned in the relevant annual report that it was caused by the sharp decline in the sales of drugs in the original key monitoring catalog with high gross profit and the centralized procureme.
In the 2021 annual report, Sihuan Pharmaceutical believes that the current generic drug business has increased by 12% year-on-year, showing that the impact of the key monitoring catalog products on the company's generic drug business has come to an end, and the performance of the generic drug segment has officially entered the rising channel, but the clinical value is not hi.
A shrinking market for well-defined drugs and high-priced generics is a foregone conclusi.
From this point of view, Sihuan Pharmaceutical's decision to divest the generic drug business at this time is also justifiab.
After the sale of the generic drug business, the company's focus will also shift to the medical beauty and innovative drug busine.
For innovative drugs, the company had planned to spin off Xuanzhu Biotechnology .
, L.
and list it independently on the Shanghai Stock Exchange's Science and Technology Innovation Boa.
The industry believes this may help companies increase their financial flexibility and ability to raise external capit.
At the same time, Sihuan Pharmaceutical directly holds about 639% of the entire issued share capital of Xuanzhu B.
After the completion of the spin-off and listing, it will still be the controlling shareholder of Xuanzhu Bio, and will still benefit from .
In terms of medical beauty, Beijing Meiyan Space, a medical beauty platform under Sihuan Pharmaceutical, is the exclusive agent of South Korea’s Hugel’s blockbuster product “Le Tibao”, which was approved in China at the end of 2020, becoming the fourth type A meat to be approved for listing in China Poisonous toxi.
In addition, the company currently has more than 10 products under research in China, including Tongyan needles, girls needles, collagen and lipolysis produc.
All the above agents and self-developed medical and beauty products are expected to be launched in the next three to four yea.
Approved for listi.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
